DrugPatentWatch Database Preview

Details for Patent: 7,572,935

« Back to Dashboard

Which drugs does patent 7,572,935 protect, and when does it expire?

Patent 7,572,935 protects APLENZIN and is included in one NDA.

This patent has fifty-three patent family members in eighteen countries.

Summary for Patent: 7,572,935

Title:	Modified release formulations of a bupropion salt
Abstract:	The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Inventor(s):	Oberegger; Werner (Mississauga, CA), Maes; Paul (Toronto, CA), Turchetta; Stefano (Rome, IT), Massardo; Pietro (Rome, IT), Saleh; Mohammad Ashty (Oakville, CA)
Assignee:	Biovail Laboratories International S.R.L. (St. Michael, BB)
Application Number:	11/762,840
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,572,935
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 7,572,935

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Valeant Pharms North	APLENZIN	bupropion hydrobromide	TABLET, EXTENDED RELEASE;ORAL	022108-001	Apr 23, 2008		RX	Yes	No			Y
Valeant Pharms North	APLENZIN	bupropion hydrobromide	TABLET, EXTENDED RELEASE;ORAL	022108-002	Apr 23, 2008		RX	Yes	No			Y
Valeant Pharms North	APLENZIN	bupropion hydrobromide	TABLET, EXTENDED RELEASE;ORAL	022108-003	Apr 23, 2008		RX	Yes	Yes			Y

International Family Members for US Patent 7,572,935

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006261788
Australia	2008285660
Australia	2008320915
Canada	2578626